Synovial Sarcoma clinical trials at UCSF
1 research study open to eligible people
Showing trials for
ACTengine® IMA203 Combined With mRNA-4203
open to eligible people ages 18 years and up
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
San Francisco, California and other locations